Markets:

Overview

News

Currencies

International

Treasuries

Vertex Pharmaceuticals (NQ:VRTX)

470.60 -7.32 (-1.53%)

Streaming Delayed Price Updated: 3:37 PM EST, Feb 9, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Vertex Pharmaceuticals

< Previous 1 2 3 4 5 6 7 8 9

...

63 64 Next >

2 Nasdaq 100 Stocks Worth Investigating and 1 We Turn Down

December 28, 2025

The Nasdaq 100 (^NDX) is home to some of the biggest success stories in tech and growth investing. However, certain stocks in the index face challenges like profitability concerns, rising costs, or...

Via StockStory

Topics Electric Vehicles World Trade

3 Supercharged Growth Stocks to Buy and Hold Into the 2030s ↗

December 28, 2025

Growth stocks fall in and out of favor with investors, but quality businesses are always worth buying.

Via The Motley Fool

Topics Artificial Intelligence

Forget Moderna Stock, This is a Much Better Buy ↗

December 27, 2025

This stock is a great choice for cautious and aggressive investors.

Via The Motley Fool

Topics Intellectual Property

The $1.7 Billion Pivot: Agios Pharmaceuticals (AGIO) and the New Frontier of Oral Thalassemia Therapy

December 24, 2025

On December 23, 2025, the biotechnology landscape shifted for thousands of patients living with chronic anemia. The U.S. Food and Drug Administration (FDA) granted approval to AQVESME (mitapivat),...

Via PredictStreet

Topics Economy

Is CRISPR Therapeutics Stock Yesterday's News? ↗

December 24, 2025

The biotech sells blood disorders treatment, Casgevy.

Via The Motley Fool

Moderna (MRNA): The “Act 2” of an mRNA Pioneer – A 2025 Deep Dive

December 22, 2025

As of December 22, 2025, Moderna, Inc. (NASDAQ: MRNA) stands at a critical juncture in its corporate evolution. Once the poster child for the biotechnology industry’s rapid response to the global...

Via PredictStreet

Topics Earnings Initial Public Offering Intellectual Property

Vertex Pharmaceuticals Inc (NASDAQ:VRTX): A GARP Case Study in Affordable Growth ↗

December 22, 2025

Vertex Pharmaceuticals (VRTX) exemplifies GARP investing, offering strong earnings growth, top profitability, and a debt-free balance sheet at a reasonable market valuation.

Via Chartmill

2 Cash-Producing Stocks to Consider Right Now and 1 We Find Risky

December 21, 2025

Generating cash is essential for any business, but not all cash-rich companies are great investments. Some produce plenty of cash but fail to allocate it effectively, leading to missed opportunities.

Via StockStory

Is CRISPR Therapeutics a Buy, Sell, or Hold in 2026? ↗

December 19, 2025

Next year could be crucial for the company as sales for its only approved treatment could take off.

Via The Motley Fool

2 Reasons to Watch VRTX and 1 to Stay Cautious

December 17, 2025

Since June 2025, Vertex Pharmaceuticals has been in a holding pattern, posting a small return of 0.5% while floating around $450.68. The stock also fell short of the S&P 500’s 13.6% gain during that...

Via StockStory

Topics Stocks

12 Days of Investing: My Top 12 Stocks to Buy Before 2026 ↗

December 15, 2025

The following players span a variety of industries, so if you pick up more than one, you may gain in diversification.

Via The Motley Fool

Topics Artificial Intelligence

Vertex Pharmaceuticals (NASDAQ:VRTX) Combines Strong Growth with Technical Breakout Potential ↗

December 15, 2025

Vertex Pharmaceuticals (VRTX) shows strong growth fundamentals and a positive technical breakout setup, combining high earnings forecasts with a promising stock chart pattern.

Via Chartmill

2 Healthcare Stocks to Buy Ahead of the New Year ↗

December 12, 2025

These companies could innovate their way to success.

Via The Motley Fool

Beyond AI: How Non-AI Tech Innovations are Fueling a New Era of Stock Market Growth

December 11, 2025

As 2025 draws to a close, a powerful undercurrent of technological innovation, extending far beyond the pervasive influence of artificial intelligence, is demonstrably reshaping the global stock...

Via MarketMinute

Topics Artificial Intelligence Economy Emissions

1 Large-Cap Stock to Consider Right Now and 2 Facing Challenges

December 08, 2025

Large-cap stocks are known for their staying power and ability to weather market storms better than smaller competitors. However, their sheer size makes it more challenging to maintain high growth...

Via StockStory

Down 10%, Should You Buy the Dip on Vertex Pharmaceuticals? ↗

December 06, 2025

The stock has fallen from a peak back in April.

Via The Motley Fool

1 Reason I'll Never Sell Vertex Pharmaceuticals Stock ↗

December 04, 2025

The stock has climbed in the double-digits in recent years.

Via The Motley Fool

Topics Intellectual Property

Which S&P500 stocks are moving on Wednesday? ↗

December 03, 2025

Wondering what's happening in today's session for the S&P500 index? Stay informed with the top movers within the S&P500 index on Wednesday.

Via Chartmill

Why Vertex Pharmaceuticals (VRTX) Stock Is Up Today

December 03, 2025

Shares of biotech company Vertex Pharmaceuticals (NASDAQ:VRTX) jumped 6.2% in the afternoon session after Morgan Stanley upgraded its rating on the stock to "Overweight" from "Equal-Weight" and...

Via StockStory

Topics Artificial Intelligence Economy

What's going on in today's session: S&P500 movers ↗

December 03, 2025

Stay updated with the movements of the S&P500 index in the middle of the day on Wednesday. Discover which stocks are leading as top gainers and losers in today's session.

Via Chartmill

2 Brilliant Growth Stocks to Buy Now and Hold for the Long Term ↗

December 03, 2025

Both can help drive excellent returns for patient, disciplined investors.

Via The Motley Fool

Topics Artificial Intelligence

3 Top Stocks to Buy in December ↗

December 01, 2025

These stocks deserve a spot on investors' shopping lists this holiday season.

Via The Motley Fool

Meet the Beaten-Down Biotech Stock Cathie Wood Loves That Wall Street Says May Soar 50% ↗

November 30, 2025

This company's first product has started to generate revenue.

Via The Motley Fool

Topics ETFs

Vertex (VRTX) Q3 2025 Earnings Call Transcript ↗

November 27, 2025

Vertex (VRTX) Q3 2025 Earnings Call Transcript

Via The Motley Fool

Topics Earnings

Where Will Vertex Pharmaceuticals Be in 5 Years ↗

November 27, 2025

Prediction: Vertex will be much larger by the end of the decade.

Via The Motley Fool

2 Healthcare Stocks For Beginner Investors With a 30-Year Time Horizon ↗

November 23, 2025

If you're investing for the next 30 years, don't overlook these top stocks.

Via The Motley Fool

Topics Intellectual Property

Vertex Pharmaceuticals (VRTX) Stock Trades Up, Here Is Why

November 21, 2025

Shares of biotech company Vertex Pharmaceuticals (NASDAQ:VRTX) jumped 2.7% in the afternoon session after comments from a key Federal Reserve official bolstered hopes for an interest rate cut.

Via StockStory

Topics Artificial Intelligence Economy Supply Chain

2 Inflation-Proof Growth Stocks That Could Outperform the Market ↗

November 20, 2025

Inflation should have a minimal impact on these companies' financial results. And they also boast excellent growth prospects.

Via The Motley Fool

Topics Economy Intellectual Property

Vertex Pharmaceuticals Inc (NASDAQ:VRTX) Presents a Compelling Case for Value Investors ↗

November 20, 2025

Vertex Pharmaceuticals (VRTX) presents a strong value investment case with a low P/E ratio, robust profitability, a healthy debt-free balance sheet, and accelerating earnings growth.

Via Chartmill

Agios Pharmaceuticals Plunges Over 50% as Sickle Cell Drug Delivers Mixed Phase 3 Results

November 19, 2025

Boston, MA – November 19, 2025 – Agios Pharmaceuticals, Inc. (NASDAQ: AGIO) experienced a dramatic and immediate market backlash, with its stock plummeting over 51.00% following the announcement of...

Via MarketMinute

< Previous 1 2 3 4 5 6 7 8 9

...

63 64 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.